Crystallization and preliminary X-ray diffraction analysis of the catalytic domain of recombinant human phosphodiesterase 3B

Acta Crystallogr D Biol Crystallogr. 2004 Jan;60(Pt 1):169-71. doi: 10.1107/s0907444903025101. Epub 2003 Dec 18.

Abstract

The catalytic domain of human phosphodiesterase 3B has been cloned, expressed in Escherichia coli and purified in the presence of the PDE3 inhibitors IBMX (3-isobutylmethylxanthine) or MERCK1 by affinity chromatography. Initial screening of crystallization conditions for these complexes in the hanging-drop vapor-diffusion mode resulted in three different crystal forms, all characterized by quite large unit-cell parameters, elevated solvent content and poor diffraction quality. Subsequent optimization of these conditions led to crystals that diffract to 2.4 A and belong to space group C2, with unit-cell parameters a = 146.7, b = 121.5, c = 126.3 A, beta = 100.6 degrees. Rotation-function analysis indicates that the asymmetric unit contains four copies of the monomeric enzyme, corresponding to a solvent content of 64%. To solve the structure of the PDE3B catalytic domain, molecular replacement as well as multiple isomorphous replacement methods are currently being utilized.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • 1-Methyl-3-isobutylxanthine / chemistry
  • 3',5'-Cyclic-AMP Phosphodiesterases / chemistry*
  • Catalytic Domain
  • Chromatography, Affinity
  • Crystallization
  • Crystallography, X-Ray
  • Cyclic Nucleotide Phosphodiesterases, Type 3
  • Humans
  • Phosphodiesterase Inhibitors / chemistry
  • Recombinant Proteins / chemistry

Substances

  • Phosphodiesterase Inhibitors
  • Recombinant Proteins
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 3
  • PDE3B protein, human
  • 1-Methyl-3-isobutylxanthine